Pan-African Journal of Health And Psychological Sciences
ISSN: 3093-4737 | www.pajhps.org
Vol.2, Issue 2 | April-June 2026

Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms

[1]Afsar Ali , [2]Tawqeer Shafi , [2]Imtiyaz Hussain
[1]B Pharm (Student), School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India
[2] Assistant Professor, School of Pharmacy , Desh Bhagat University, Mandi Gobindgarh Punjab, India

Corresponding Author
Dr. Tawqeer Shafi
Assistant Professor
Orcid id :- 0009-0005-8773-3745
Email: iamtawqeer5@gmail.com

Abstract
Autoimmune diseases are diseases that occur due to the breakdown in the immunity and causes the immune system to destroy tissues in the body as a consequence of biological malfunction in the immune system. The advances of the immunology and of the cellular engineering are turning the field to an area of precision immunotherapy, which will likely result in the revival of the long-term immunity tolerance. CAR-T cell therapy which was developed to treat cancer including autoreactive B cell (e.g., CD19+) has also been demonstrated effective in refractory Systemic Lupus Erythematosus and Myasthenia Gravis. Rather than immunosuppressing B cells worldwide, more specific Chimeric Autoantibody Receptor T cells eliminate B cells that secrete pathogenic autoantibodies. Parallel solutions- such as Regulatory T cell therapy and Tolerogenic Dendritic Cells- work towards induction of antigen-specific tolerance and new modalities such as biomaterial-based immunomodulation, antigen delivery, CRISPR/Cas9 gene editing, and immune checkpoint agonists open up treatment options. It is estimated that the use of artificial intelligence and multi-omics in the sphere of precision medicine will allow predicting diseases, endotype, and treatment depending on the biomarkers. The next-generation interventions, including scalable allogeneic CAR-T/CAR-NK cells, combination therapy, and real-time immune surveillance have a massive potential of transforming the AID therapy towards curative immune restoration, rather than chronic symptom management due to challenge of cytokine release syndrome, long-term safety, low-cost, and barrier to implementation.
Keywords: Autoimmune disease, CRISPR/Cas9, Myasthenia gravis, Immunotherapy, Systemic lupus erythematosus , Rheumatoid arthritis

1. Introduction

Autoimmune diseases (AIDs) represent a heterogeneous group of disorders characterized by a breakdown in immune tolerance, resulting in self-directed immune responses that damage healthy

How to cite this article: Ali et al. 92026). **Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms. Pan-African Journal of Health and Psychological Sciences. Vol 2, Issue 2, April-June 2026. https://doi.org/10.64261/txxhnb84.**

ISSN: 3093-4737

tissues [1]. Over 80 autoimmune conditions have been identified, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type 1 diabetes mellitus (T1D), inflammatory bowel diseases (IBD), and autoimmune thyroiditis [2]. Collectively, these conditions affect 5–10% of the global population, with an increasing incidence driven by genetic predisposition, environmental triggers,and lifestyle changes [3]. Autoimmune disorders disproportionately affect women of reproductive age, making them a leading cause of chronic illness and disability in this demographic [4]. The therapeutic man agement of autoimmune diseases has traditionally relied on systemic immunosuppressants such as corticosteroids, methotrexate, azathioprine, and calcineurin inhibitors. More recently, biologics targeting tumor necrosis factor (TNF), IL-6, CD20,and integrins have significantly improved patient outcomes [5]. Despite these advances, several challenges persist. Current treatments are largely palliative rather than curative, require long-term use, and carry risks of opportunistic infections, malignancy, and systemic toxicity [6]. Moreover,therapeutic response rates remain suboptimal, with a subset of patients experiencing refractory disease or frequent relapses [7].

Over the past decade, advances in molecular immunology, cell engineering, and computational biology have catalyzed a paradigm shift from broad immunosuppression to precision immunotherapy [8]. This shift is motivated by the goal of not only suppressing autoreactive immune responses but also restoring durable tolerance [9]. Cutting-edge strategies include chimeric antigen receptor (CAR) T-cell therapy, regulatory T cell (Treg) augmentation, tolerogenic dendritic cell (tolDC) therapy, Fc receptor (FcRn) modulation, complement inhibition, gene editing, and biomaterial-based immunomodulation. Furthermore, precision medicine, powered by artificial intelligence (AI) and biomarker discovery, is enabling individualized treatment approaches that maximize efficacy while minimizing risk [10].This review synthesizes the latest advances in immunotherapeutic strategies for autoimmune diseases. We examine current and emerging modalities, their mechanisms of action, clinical trial outcomes, and translational potential. Additionally, we explore precision medicine applications, economic and regulatory considerations, and the clinical challenges inherent to immunotherapy Ultimately, this article aims to provide a comprehensive perspective on the future of autoimmune disease management, where therapies may progress from suppressing disease [11].

2. Current Landscape of Immunotherapy for Autoimmune Diseases

2.1. Chimeric Antigen Receptor (CAR) T-Cell Therapy

Car T-cell therapy that was initially used to treat hematologic malignancies is currently being used to treat autoimmune diseases [12]. Its main justification is that the autoreactive B cells are essential in maintaining pathogenic autoantibodies in diseases like SLE, MS and myasthenia gravis (MG) [13]. Mechanistically, CAR T cells are derived by isolating T cells of the patient, transducing them in a viral plasmid with an expression encoding one of the chimeric receptors (CD19), and restoring them to the patient following lymphodepletion. Upon entering circulation, CAR T cells identify and kill CD19-expressing B cells against which memory B cells, which cause disease chronicity, also belong. CD19-CAR T cells in small case series of refractory SLE have led to deep clinical responses, restored normal levels of complement and autoantibody clearance and the remissions have lasted over 12 months following infusion [14].

ISSN: 3093-4737

The CAR T-cell therapy has more comprehensive and persistent depletion (including plasma cell precursors, rituximab spares) than conventional B-cell-depleting therapies (e.g., rituximab). Notably, response durability increases the chances that the one-time therapy, instead of the continuous maintenance therapy, is possible.Safety is a critical issue. CRS and neurotoxicity, frequent in the oncology environment, also seem to have a lighter manifestation in autoimmune patients and should be closely monitored [15].

Table 1 presents the existing clinical situation of CAR-T cell-based immunotherapy in autoimmune diseases by displaying early-phase trials and case reports in which predominantly CD19-positive B cells were targeted. Early investigations show good response rates especially in systemic lupus erythematotus and good results are also seen in lupus nephritis, myositis, myasthenia gravis and antisynthetase syndrome. The results show persistent B-cell depletion, serological normalization and prolonged clinical remission highlighting the use of CAR-T therapy in refractory autoimmune disorders as a disease-modifying treatment.

Table 1. Summary of Clinical Studies Evaluating CD19 CAR-T and CAAR-T Therapies in Autoimmune Diseases

S.NO.	**Disease Indication**	Target Antigen	Trial/Study (Phase)	Key Outcomes	Reference
1.	**Systemic Lupus Erythematosus (SLE)**	CD19	Case series, Nature Medicine 2022 (n=5)	All patients achieved drug-free remission, normalization of serologic markers, B-cell aplasia lasting >100 days	[16]
2.	**Systemic Lupus Erythematosus (SLE)**	CD19	NCT05030779 (Phase I/II)	Early reports: ≥80% of patients achieved complete clinical response; sustained remission in some beyond 1 year	[17]

ISSN: 3093-4737

3.	**Refractory SLE & Lupus Nephritis**	CD19	NCT05474885 (Phase I/II)	Primary endpoint: safety and feasibility; secondary: renal response, SLEDAI score	[18]
4.	**Idiopathic Inflammatory Myopathies (Dermatomyositis, Polymyositis)**	CD19	NCT06337727 (Phase I)	Evaluating muscle strength, CK normalization, and safety	[19]
5.	**Myasthenia Gravis (MG)**	CD19	NCT04561557 (Phase I/II)	Interim data: marked reduction in MG-ADL scores, sustained symptom relief, reduced acetylcholine receptor antibody titers	[17]
6.	**Antisynthetase Syndrome (subset of myositis)**	CD19	Investigator-initiated (Case report, 2023)	Complete remission with disappearance of anti-Jo1 antibodies after CAR-T infusion	[19]
7.	**Pemphigus Vulgaris (exploratory)**	CAAR-T (Desmoglein-3)	NCT04422912 (Phase I)	First-in-human CAAR-T approach, targeting autoreactive B cells specific for desmoglein-3	[20]

How to cite this article: Ali et al. 92026). **Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms. Pan-African Journal of Health and Psychological Sciences. Vol 2, Issue 2, April-June 2026. https://doi.org/10.64261/txxhnb84.**

ISSN: 3093-4737

8.	**Multiple Autoimmune Diseases (basket trial: SLE, MS, RA)**	CD19	NCT06089479 (Phase I, Allogeneic CAR-T)	Evaluating universal CAR-T safety, expansion, and efficacy	[21]

2.3. Regulatory T Cell (Treg) Immunotherapy

Regulatory T cells (Tregs) are central to maintaining immune tolerance by suppressing autoreactive effector T cells and promoting homeostasis. Dysfunction or deficiency of Tregs is implicated in the pathogenesis of multiple autoimmune diseases [22]. Polyclonal Treg infusion involves ex vivo expansion of autologous Tregs followed by reinfusion. This approach has shown safety and preliminary efficacy in early-phase trials for T1D and graft-versus-host disease. Antigen-specific Tregs, engineered to recognize specific autoantigens or expressed as CAR-Tregs,offer greater precision by targeting disease-relevant immune responses while sparing protective immunity [23].

Clinical trials are underway to evaluate Treg therapies in MS, T1D, and autoimmune liver diseases. Adoptive transfer protocols involve leukapheresis, ex vivo culture with IL-2 and rapamycin to promote stable Treg phenotypes, and reinfusion [24]. Challenges include ensuring Treg stability in inflammatory environments and preventing conversion to pro-inflammatory phenotypes. Adjunctive methods such as low dose IL-2 therapy are selective in expanding the endogenous Tregs and have demonstrated promising efficacies in SLE and RA. CRISPR/Cas9 editing can further enhance Treg activity by repairing mutations in genes like that of the FOXP3 or IL2RA that can be used to generate Treg-based immunotherapies to promote antigen-specific immune tolerance [25, 26].

2,4. Tolerogenic Dendritic Cell (TolDC) Therapy

Dendritic cells (DCs) are professional antigen-presenting cells that can either activate immune responses or induce tolerance depending on their maturation state [27]. Tolerogenic dendritic cells (tolDCs) are engineered or pharmacologically conditioned to present antigen in a non-inflammatory context, thereby inducing Tregs and anergy in autoreactive T cells.TolDCs have been investigated in RA,MS, and Crohn's disease. In RA, phase I trials of intra-articular tolDC administration demonstrated safety, feasibility, and reduced local inflammation. Similarly, in MS, autologous tolDCs pulsed with myelin peptides induced favorable immune modulation without systemic toxicity [28]. Routes of administration remain under investigation. Intradermal delivery allows systemic immune reprogramming, whereas intra-articular or intranodal delivery provides localized effects. The durability of tolerance, scalability of DC generation,and cost-effectiveness remain key translational hurdles [29]. **Figure 1 shows that under the action of immunomodulatory factors including phytochemicals, vitamin D3, IL-10, and TGF-b1, monocytes differentiate into tolerogenic dendritic cell, which results in reduced co-stimulatory molecule expression and induction and expansion of Tregs, thus preserving immune tolerance to prevent autoimmune immune responses.**

ISSN: 3093-4737



Figure 1. Differentiation and Immunoregulatory Mechanisms of Tolerogenic Dendritic Cells

This illustrates the differentiation of tolerogenic dendritic cells (tolDCs) from monocytes under the influence of immunomodulatory factors such as phytochemicals, vitamin D3, IL-10, and TGF-β1. TolDCs exhibit reduced expression of co-stimulatory molecules (MHC, PD-L1) and promote immune tolerance by inducing and expanding regulatory T cells (Tregs), thereby suppressing effector T-cell responses and maintaining immune homeostasis.

3. Emerging Immunotherapeutic Modalities

3.1. Chimeric Autoantibody Receptor (CAAR) T-Cell Therapy

CAAR T-cell therapy represents an evolution of CAR technology tailored for autoantibody-driven diseases. Instead of targeting B-cell markers broadly, CAAR T cells are engineered to express the autoantigen itself as the extracellular domain of the receptor [30]. This enables them to selectively eliminate autoreactive B cells producing pathogenic autoantibodies.In pemphigus vulgaris, for instance, CAAR T cells expressing desmoglein-3 target B cells responsible for anti-desmoglein antibodies, sparing non-pathogenic B-cell populations. This precision minimizes the risk of global B-cell depletion and preserves protective immunity [31]. Preclinical models have shown robust efficacy, and early-phase clinical trials are underway in pemphigus and MG.The advantage of CAAR T therapy lies in its disease specificity, reduced systemic immunosuppression,and potential for long-term remission.

ISSN: 3093-4737

Challenges include antigen heterogeneity, off-target effects, and the complexity of engineering patient-specific receptors. Nonetheless, CAAR T cells represent a highly promising platform for personalized autoimmune therapy [32].

3.2. Immune Checkpoint Modulation in Autoimmune Diseases

Immune checkpoint pathways, particularly CTLA-4 and PD-1, play critical roles in maintaining tolerance by inhibiting T-cell activation. Dysregulation of these pathways contributes to autoimmune pathology [33]. Therapeutic modulation seeks to restore inhibitory signaling in autoreactive T cells.Abatacept, a CTLA-4-Ig fusion protein, has demonstrated efficacy in RA by blocking CD28-mediated co-stimulation. Similarly, PD-1 agonists and engineered ligand fusion proteins are being investigated to suppress effector T-cell responses in lupus and T1D. Importantly, while checkpoint inhibitors used in oncology can precipitate autoimmune side effects, the inverse strategycheckpoint agonismmay attenuate autoimmunity.A key challenge lies in balancing immune tolerance with host defense [34]. Excessive checkpoint activation may predispose patients to infections or malignancy. Therefore, precision targeting and controlled delivery are critical to safely harnessing checkpoint pathways in autoimmunity [35].

3.3. Gene Editing Technologies

The possibilities of gene editing via CRISPR/Cas9 and other similar systems are unprecedented in terms of genetic defects and immune cells reprogramming opportunities in autoimmune diseases **[**36**].** Such strategies can be used to correct disease-related variants of IL2RA or FOXP3 in ex vivo, which restores regulatory T-cell (Treg) functions, and additionally can be used to target edit B-cell or T-cell receptors to eliminate autoreactive clones or construct tolerance-promoting receptors[37]. Besides that, adoptive cell therapies like CAR-T cells or Tregs can be instructed to knock out exhaustion-related genes to increase cellular persistence and therapeutic efficacy [38]. Preclinical models of type 1 diabetes and multiple sclerosis have established that gene-edited T cells can be successfully used to restore immune tolerance, but issues associated with efficient delivery, off-target effects and ethical concerns are major obstacles to clinical translation [39].

Table 2 indicates preclinical applications of CRISPR/Cas9 gene editing to a variety of autoimmune disease models, targeting central immune regulatory genes in T cells, B cells, and tissue-specific cells.Precise CRISPR-based immune reprogramming can protect target tissues, suppress autoimmunity and has high potential in tolerance-based therapeutics.

Table 2. Targeted CRISPR/Cas9 Editing Strategies for Restoring Immune Tolerance in Autoimmune Diseases

s.no.	Autoimmune Disease Model	Gene/Target Edited	Cell Type / Approach	Key Findings	Reference

ISSN: 3093-4737

1.	**Type 1 Diabetes (NOD mouse model)**	PD-1 / PD-L1 pathway	T cells edited for enhanced PD-1 signaling	Restored tolerance, reduced β-cell destruction, delayed diabetes onset	[40]
2.	**Type 1 Diabetes (NOD mouse model)**	Insulin gene regulatory regions	β cells (in vivo editing)	Increased β-cell survival, reduced insulitis	[41]
3.	**Systemic Lupus Erythematosus (SLE, MRL/lpr mice)**	IL2RA (CD25)	Tregs edited to enhance IL-2 responsiveness	Restored Treg stability, reduced autoantibody titers	[42]
4.	**Multiple Sclerosis (EAE mouse model)**	FOXP3	T cells engineered to express corrected FOXP3	Increased suppressive Treg function, ameliorated CNS inflammation	[41]
5.	**Rheumatoid Arthritis (CIA mouse model)**	TNF-α	Synovial fibroblasts (ex vivo editing)	Reduced inflammatory cytokine release, improved joint pathology	[43]
6.	**Inflammatory Bowel Disease (IBD)**	NOD2	Intestinal epithelial cells	Corrected susceptibility allele, improved mucosal barrier function	[44]
7.	**General Autoimmunity (in vitro platform)**	B-cell receptor (BCR) editing	Autoreactive B cells deleted via CRISPR targeting of Ig heavy chain	Eliminated autoantibody-producing clones	[45]

ISSN: 3093-4737

8.	**Treg Cell Dysfunction Models**	IL2RA / CTLA4 / FOXP3	Human Tregs (ex vivo CRISPR correction)	Restored suppressive phenotype, potential for adoptive Treg therapy	[46]

3.4. Biomaterial-Enhanced Immunotherapy

Biomaterials are being increasingly integrated into immunotherapy to improve delivery, stability, and specificity. Nanoparticle-based systems can encapsulate autoantigens and tolerogenic agents (e.g., rapamycin, IL-10), directing them to lymphoid tissues for induction of Tregs. Biodegradable scaffolds and hydrogels allow controlled release of immunomodulators at disease sites.Antigen-specific tolerance induction using nanoparticles has shown promise in preclinical models of MS (myelin peptide nanoparticles) and T1D (insulin peptide nanoparticles) [47]. The **Figure 2** explains **nanoparticle-based immunomodulation strategies** used to control unwanted immune responses. Antigen-coupled nanoparticles interact with immune cells in a way that promotes **immune tolerance** rather than activation, leading to the **expansion of regulatory T cells (Tregs)** that suppress excessive immune reactions. In parallel, nanoparticles act as targeted carriers for **immunosuppressive drugs,** allowing precise and efficient drug delivery to immune cells, thereby reducing inflammation and autoimmunity while minimizing systemic side effects.



Figure 2. Strategies of Immune Tolerance Induction and Immunosuppression via Nanoparticles. Immunomodulation with nanoparticles that show antigen-coupled nanoparticles to induce

ISSN: 3093-4737

immune tolerance and increase regulatory T cells as well as targeted delivery of immunosuppressive drugs to inhibit unwanted immune responses are controlled.

4. Precision Medicine and Biomarker Development

4.1. Artificial Intelligence in Autoimmune Disease Prediction

Artificial intelligence (AI) and machine learning are revolutionizing autoimmune disease prediction and management. Deep learning models can integrate clinical, genetic, transcriptomic, and imaging data to classify disease subtypes and predict progression [48]. For example, convolutional neural networks applied to MRI data have improved MS lesion detection.AI frameworks such as ImmunoNet are being developed to diagnose autoimmune conditions based on immune cell network profiling. Integration of multi-omics datasets (genomics, epigenomics, proteomics, metabolomics) further enables individualized risk stratification and treatment selection [49]. **Table 3 presents the use of biomarkers derived through artificial intelligence on various autoimmune diseases where multi-omic and image and clinical data are used as inputs.**

Sophisticated AI and machine-learning solutions facilitate stratification of diseases, prediction of disease activity, risk of relapse and response to treatment, which provide precision medicine strategies.

4.2. Predictive Biomarkers for Treatment Response

Biomarkers are essential for tailoring immunotherapies. Genetic markers (e.g., HLA alleles), epigenetic modifications, and proteomic signatures are under active investigation.For instance, high type I interferon signatures in SLE predict response to anifrolumab (anti-IFN receptor) [50]. B-cell subset profiling may guide use of B-cell–targeted therapies. Real-time disease monitoring using circulating microRNAs or autoantibody repertoires may inform early relapse detection.Projects like PARADISE (Prediction of Autoimmune Disease Relapse Using Systems Biology) are developing integrative platforms to identify relapse biomarkers [51].

Table 3. The AI-Derived Biomarkers for Autoimmune Disease Prediction

S.no	**Disease / Application**	AI-Derived Biomarker (Type)	Data Inputs Used	AI / ML Method	Predictive or Clinical Utility	Reference
1.	**Systemic lupus erythematosus (SLE)**	Type I interferon transcriptional signature (gene-expression score)	Peripheral blood transcriptomics, clinical metadata	Supervised classifiers (random forest, elastic net)	Predicts disease activity, stratifies responders to anti-IFN therapies	[52]

ISSN: 3093-4737

2.	**Rheumatoid arthritis (RA)**	Synovial molecular endotypes (gene-expression clusters)	Synovial biopsy RNAseq + clinical features	Unsupervised clustering + supervised prediction models	Predicts drug response (TNF inhibitors vs IL-6R/CTLA4), informs treatment selection	[53]
3.	**Multiple sclerosis (MS)**	MRI radiomic features + lesion evolution score	Longitudinal brain MRI series	Deep learning (CNN) + time-series models	Predicts conversion from CIS to definite MS and short-term disability progression	[54]
4.	**Type 1 diabetes (T1D)**	Autoantibody epitope-profile risk score (multiepitope signature)	Autoantibody panels, proteomics, HLA genotype	Gradient boosting / ensemble methods	Predicts imminent onset in at-risk individuals (months–years)	[55]
5.	**Inflammatory bowel disease (IBD)**	Gut microbiome risk signatures (taxa + functional pathways)	Shotgun metagenomics, metabolomics	Machine learning classifiers (XGBoost, SVM)	Predicts disease subtype (CD vs UC), relapse risk, and steroid-response	[56]
6.	**Myasthenia gravis (MG)**	Autoantibody titer dynamics + epitope clustering	Serial serology, clinical scores	Time-series ML and clustering	Predicts relapse risk and may guide timing of B-cell targeted therapy	[57]

ISSN: 3093-4737

7.	**Primary / systemic sclerosis**	Peripheral immune cell-composition signatures (flow cytometry + RNA)	Single-cell RNAseq, cytometry data	Graph-based ML, manifold learning	Stratifies patients into molecular subsets with differential prognosis	[58]
8.	**General / Multi-disease relapse prediction**	Multi-omic integrated relapse risk score (composite biomarker)	Genomics, transcriptomics, proteomics, clinical data	Multi-modal deep learning / ensemble integration	Real-time relapse forecasting to trigger preemptive therapy	[59]
9.	**Autoantibody-mediated disorders (biomarker discovery)**	Epitope-level autoantibody maps (peptidome risk indices)	High-throughput peptide arrays, serology	Sparse regression, feature selection pipelines	Identifies pathogenic epitopes for targeted CAAR-T or tolerizing vaccines	[60]
10.	**Treatment adherence & outcome prediction**	Behavioral + digital biomarker score	Wearables, EHR, patient-reported outcomes	Time-series ML, survival models	Predicts nonadherence and early nonresponse to optimize interventions	[61]

4.3. Personalized Immunotherapy Selection

Personalized immunotherapy requires matching patients to the most effective treatment based on molecular signatures. Clinical decision support systems (CDSS) are being designed to integrate biomarker data, patient characteristics, and predictive algorithms [62]. Treatment adherence prediction using AI can further optimize long-term outcomes.Ultimately, biomarker-driven precision medicine holds the key to maximizing therapeutic benefit while minimizing toxicity [63].

5. Clinical Challenges and Safety Considerations

5.1. Immune-Related Adverse Events

A major challenge of immunotherapy lies in managing immune-related adverse events (irAEs). In CAR T-cell therapy, cytokine release syndrome (CRS) is the most common complication, caused by massive cytokine production following CAR T expansion[64]. Clinical manifestations include fever, hypotension, and organ dysfunction. CRS management involves IL-6 blockade (tocilizumab) and corticosteroids. Neurotoxicity, another CAR T-associated risk, is less common in autoimmunity than oncology but requires vigilance. Checkpoint-based therapies can trigger

ISSN: 3093-4737

paradoxical autoimmunity, such as colitis, thyroiditis, or arthritis [65].

5.2. Disease Flare Management

Immunotherapy may paradoxically trigger disease flares due to immune activation. Risk factors include high baseline autoantibody titers and pro-inflammatory cytokine profiles. Combination therapies, such as pairing tolerogenic agents with CAR T cells, may mitigate flare risk.Balancing immunosuppression with immune restoration remains a delicate task, requiring personalized treatment sequencing [66].

5.3. Long-term Safety and Durability

Immunotherapy has unresolved questions remaining including; the durability of immune tolerance and delayed side effects. To take an example, it is yet unclear whether remissions induced by CAR T-cell-therapy will be maintained following B cells re-emergence. The other potential danger is secondary cancer formation due to the genetic alterations, which are introduced in the course of treatment. These risks must be managed by continued long-term research and post-marketing surveillance to learn more about them.

6. Economic Considerations and Healthcare Impact

6.1. Cost-Effectiveness Analysis

Cellular therapies like CAR T are resource-intensive, with costs exceeding several hundred thousand dollars per patient. Cost-effectiveness analyses weigh these upfront expenses against quality-adjusted life years (QALYs) gained and potential reductions in lifelong therapy costs. Early modeling suggests that curative potential may offset high upfront costs [67].

6.2. Healthcare System Integration

Integration of advanced immunotherapies into health systems requires specialized infrastructure, trained personnel, and equitable access frameworks. Resource-limited settings face additional challenges in affordability and scalability. Global collaboration and policy frameworks will be needed to democratize access to next-generation therapies [68].

7. Regulatory Landscape and Clinical Translation

7.1. FDA Approval Pathways

The U.S. Food and Drug Administration (FDA) has developed several accelerated approval paths that would facilitate the communication of promising therapies, such as immunotherapies and cellular therapies [69]. They are supposed to fill unmet medical requirements particularly serious or life threatening conditions like advanced cancers [70]. These pathways consist of one named the Breakthrough Therapy Designation, which is bestowed upon drugs that show substantial improvement over existing therapies based on first clinical evidence [71]. Many immune checkpoint inhibitors and CAR-T cell therapies are assigned this designation with the effect of accelerating the development and approval process [72]. Accelerated Approval process allows drugs to be approved based on surrogate or intermediate effects e.g. tumor shrinkage or biomarker changes, rather than final clinical effects e.g. overall survival [73]. This is most important in cancer research, as a delay in obtaining long-term data can cause postponement of life-saving treatment. However, in the process of drug approval, the sponsors will be required to

ISSN: 3093-4737

conduct confirmatory trials to determine clinical benefit. Otherwise, approval can be withdrawn as it has been with certain PD-1/PD-L1 inhibitors.The necessity to organize the regulatory standards efforts on a global scale, also contributes significantly to the provision of timely global access to new treatments. Efforts such as the International Council Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) and Project Orbis (hosted by the Oncology Center of Excellence of the FDA) to harmonise regulatory requirements and permit parallel submissions across countries Project Orbis can be an example as the FDA, EMA and other national health authorities can conduct a joint assessment of oncology drugs, eliminating duplication and reducing approvals on an international scale [74]. Together, these pathways and working group activities will ensure that novel immunotherapies reach patients within shorter time frames, and that safety and efficacy outcomes are preserved to optimal standards in international markets [75].

7.2. Clinical Trial Design Optimization

Clinical trial design has been optimized to help speed up the development of immunotherapies, especially in complex and heterogeneous diseases, such as autoimmune diseases [76]. New methods are being developed including but not limited to adaptive trial methodologies, biomarker-based patient selection, and optimized endpoint approaches which are becoming more and more used to enhance the efficiency of a trial, decrease costs, and increase the chances of success [77]. With adaptive trial designs, key trial parameters (e.g., dosing, patient stratification, or sample size) can be pre-specified to be changed in response to interim analyses [78]. Such flexibility would enable sponsors to detect signs of efficacy or futility earlier and reduce the time spent on ineffective therapies and speed up the regulatory decision-making process [79]. Adaptive designs are particularly useful in immunotherapy trials where responses observed in a cancer population or in an autoimmune population are variable and occasionally delayed.This is called biomarker-driven patient selection, improving clinical trial accuracy and relevance by recruiting respondents who are most likely to respond to a specific therapy [80]. In the case of autoimmune diseases, this may involve the selection of patients according to a certain genetic pattern, cytokine pattern or immune cell signature. Now these enrichment strategies enhance the power of the trial and minimize variability, and may expose differences in responses in subgroups that would otherwise be hidden in heterogeneous populations [81].

Particularly important is the endpoint optimization in trials in autoimmune diseases, where clinical outcomes may be subjective, or may change gradually with time [82]. Symptom scores or flare rates are not necessarily sensitive conventional end-points. Consequently, composite endpoints, objective biomarkers [83].

C-reactive protein, autoantibody titersand patient-reported outcome measures (PROM) are increasingly adopted to describe meaningful therapeutic effects. These optimized endpoints can be incorporated into trial design to help capture actual clinical benefit and increase the chances of regulatory approval [84].

Through the combination of adaptive methods, biomarker-mediated stratification, and endpoints optimization, immunotherapy and autoimmune disease clinical trials are being made more efficient, targeted, and representative of real-world efficacy [85].

ISSN: 3093-4737

8. Future Directions and Emerging Opportunities

8.1 Next Generation Cellular Therapies.

Some of the current developments to universal or allogeneic CAR-T platforms will help make treatment faster, less expensive, and more accessible. These off-the-shelf therapies do not require any specialized production, and thus, it is less expensive and requires less time to manufacture. Allogeneic CAR-T technologies are being made safer with the help of CRISPR and other gene-editing technologies to prevent immune rejection and graft-versus-host disease. CAR-NK therapies also are also becoming increasingly popular as safer and more scalable alternatives, and less susceptible to cytokine release syndrome. Natural killer cells have the ability to attack tumor cells without antigen presentation and this gives them flexibility in tumour recognition. Nonetheless, their maintenance and efficient transport into tumor locations is a research problem. The other prospective avenue is with tissue-resident memory T cells (TRM), which offer localized and long-lasting immune patrol. The application of TRM may enhance the management of the solid tumor and recurrence prevention in the long run.

8.2 Immunotherapy Strategies in Combinations.

The integration of dissimilar immunotherapy is an order of the day in combating resistance to mono-therapeutic approaches. Sequential and concurrent methods of administration are under investigation in order to maximise safety and efficacy. Combined or synergistic therapy of various immune pathways, i.e. checkpoint inhibitors and cytokine modulators, can stimulate antitumor effects. On the same note, a combination of CAR-T cell therapy and checkpoint blockade can maintain a long-lasting response. The next generation of immunotherapy is taking the form of personalized combination strategies based on tumor genomics and immune profiling. Machine learning and computer simulation are increasingly used to forecast the most efficient treatment regimen and dosage of every patient.

8.3 Technological Innovations

The immunotherapies are changing the way they are monitored and managed with the introduction of emerging technologies. Immune monitors and wearable biosensors are real-time products that allow monitoring of immune reactions and toxicity early on. Closed-loop therapeutic systems have the ability to calculate doses automatically depending on patient data, thus enhancing accuracy and safety. The integration of telemedicine facilitates follow-ups at a distance, which will guarantee the availability of care even outside the clinic. All these online and digital innovations hold more personalized, efficient, and lasting results in immunotherapy.

9. Conclusion

Immunotherapy has been used over the last ten years to transform the treatment of cancer and autoimmune diseases. Previously in the field of oncology, immune modulation is currently revolutionizing the state of rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease. The new immunologic therapies (biologics, checkpoint inhibitors, CAR-T and CAR-NK), and new combination regimens are reestablishing immune balance and enhancing long-term outcomes. The new technologies such as universal cellular therapy, tissue resident memory T-cell targeting, and closed-loop drug delivery will be even more precise.

How to cite this article: Ali et al. 92026). **Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms. Pan-African Journal of Health and Psychological Sciences. Vol 2, Issue 2, April-June 2026. https://doi.org/10.64261/txxhnb84.**

ISSN: 3093-4737

The personalisation of care and minimisation of costs are being brought about by telemedicine and real time monitoring of immune. The Breakthrough Therapy Designation and Project Orbis regulatory schemes by the FDA are hastening the way to innovative treatment. Nevertheless, some obstacles still exist: the mechanisms of diseases are not fully understood, and we have little evidence of their long-term safety, and predictive biomarkers are absent. Major barriers are also caused by equity and accessibility especially in low-resource settings. Multi-omics, predictive algorithms and early intervention are the strategy of proactive, person-centered modulation of autoimmune therapy in the future. Scalable and safe cellular therapies can provide permanent remission and a combination of therapies reduces side effects. It will be necessary to collaborate in cross-disciplinary teamwork, innovate and collaborate globally to meet this vision. Finally, immunotherapy might enter the new phase of immunology and regenerative medicine as it can be used to prevent and cure, rather than treat, autoimmune diseases.

References

1. Abacar, K., et al., *How underappreciated autoinflammatory (innate immunity) mechanisms dominate disparate autoimmune disorders.* Frontiers in Immunology, 2024. **15**: p. 1439371.
2. Frazzei, G., et al., *Preclinical autoimmune disease: a comparison of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes.* Frontiers in immunology, 2022. **13**: p. 899372.
3. Baker, R.E., et al., *Infectious disease in an era of global change.* Nature reviews microbiology, 2022. **20**(4): p. 193-205.
4. Angum, F., et al., *The prevalence of autoimmune disorders in women: a narrative review.* Cureus, 2020. **12**(5).
5. Li, P., Y. Zheng, and X. Chen, *Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics.* Frontiers in pharmacology, 2017. **8**: p. 460.
6. Singh, P., A. Mishra, and S.K. Mishra, *A comprehensive analysis of the challenges and potential side effects of radiation therapy for palliative cancer treatment.* Médecine Palliative, 2024. **23**(2): p. 75-91.
7. Randall, M.P. and M.A. Spinner, *Optimizing treatment for relapsed/refractory classic Hodgkin lymphoma in the era of immunotherapy.* Cancers, 2023. **15**(18): p. 4509.
8. Valentinuzzi, D. and R. Jeraj, *Computational modelling of modern cancer immunotherapy.* Physics in Medicine & Biology, 2020. **65**(24): p. 24TR01.
9. Srivastava, S., et al., *Revolutionizing immunotherapy: unveiling new horizons, confronting challenges, and navigating therapeutic frontiers in CAR-T Cell-Based gene therapies.* ImmunoTargets and Therapy, 2024: p. 413-433.
10. Șerban, M., C. Toader, and R.-A. Covache-Busuioc, *CRISPR and Artificial Intelligence in Neuroregeneration: Closed-Loop Strategies for Precision Medicine, Spinal Cord Repair, and Adaptive Neuro-Oncology.* International Journal of Molecular Sciences, 2025. **26**(19): p. 9409.
11. Fu, Y., et al., *Breaking barriers: advancing cellular therapies in autoimmune disease m*

anagement. Frontiers in immunology, 2024. **15**: p. 1503099.
12. Schett, G., A. Mackensen, and D. Mougiakakos, *CAR T-cell therapy in autoimmune diseases.* The Lancet, 2023. **402**(10416): p. 2034-2044.
13. Akamine, H. and A. Uzawa, *Pathogenic Role of Age-Associated B Cells in Autoimmune Disorders and Myasthenia Gravis.* Clinical and Experimental Neuroimmunology, 2025.
14. Hill, J.A. and S.K. Seo, *How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.* Blood, The Journal of the American Society of Hematology, 2020. **136**(8): p. 925-935.
15. Russell, A.L., *Non-Genotoxic Anti-CD117 Conditioning for Hematopoietic Stem Cell Transplantation and Gene Therapy Applications*. 2021, Emory University.
16. Ryzhaya, N., et al. *The Impact of Collecting Electronic Patient-Reported Outcomes (ePROs) Between Visits on Rheumatological Care: A Scoping Review*. in *The Journal of Rheumatology*. 2025. The Journal of Rheumatology.
17. Wu, D., et al., *CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.* Frontiers in Immunology, 2025. **16**: p. 1613878.
18. Li, G., et al., *Breaking boundaries: chronic diseases and the frontiers of immune microenvironments.* Med Research, 2025.
19. Wang, X., et al., *Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis.* Cell, 2024. **187**(18): p. 4890-4904. e9.
20. Lundgren, D.K., et al., *Antigen-specific B cell depletion with desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) for targeted therapy of mucosal pemphigus vulgaris.* The Journal of Immunology, 2020. **204**(1_Supplement): p. 238.2-238.2.
21. Hagen, M., et al., *POS0062 SAFETY AND PRELIMINARY EFFICACY OF CD19 CAR T-CELL TREATMENT IN RHEUMATIC DISEASE–DATA FROM THE PHASE I/II CASTLE BASKET STUDY.* Annals of the Rheumatic Diseases, 2025. **84**: p. 369-370.
22. Goswami, T.K., et al., *Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges.* Human vaccines & immunotherapeutics, 2022. **18**(1): p. 2035117.
23. Selck, C. and M. Dominguez-Villar, *Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation.* Frontiers in immunology, 2021. **12**: p. 661875.
24. Steiner, R. and N. Pilat, *The potential for Treg-enhancing therapies in transplantation.* Clinical and Experimental Immunology, 2023. **211**(2): p. 122-137.
25. Sakaguchi, S., R. Kawakami, and N. Mikami, *Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective.* Immunotherapy Advances, 2023. **3**(1): p. ltad007.
26. Safari, F., et al., *CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis.* Immunopharmacology and immunotoxicology, 2018. **40**(3): p. 201-211.
27. Obregon, C., et al., *Update on dendritic cell-induced immunological and clinical tolerance.* Frontiers in immunology, 2017. **8**: p. 1514.
28. Long, E.-L., et al., *Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2*

(AuToDeCRA-2) study: protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for rheumatoid arthritis. Trials, 2025. **26**(1): p. 278.
29. Priya, S., et al., *Revolutionizing rheumatoid arthritis treatment with emerging cutaneous drug delivery systems: overcoming the challenges and paving the way forward.* Nanoscale, 2025. **17**(1): p. 65-87.
30. Gerson, D.K., *Precision medicine for Autoimmunity: From CAAR-T Cells to AI-Driven CRISPR-based therapies, challenges and perspectives.*
31. Lim, Y.L., et al., *Autoimmune pemphigus: latest advances and emerging therapies.* Frontiers in Molecular Biosciences, 2022. **8**: p. 808536.
32. Protić-Rosić, I., et al., *Chimeric Autoantibody Receptor-and/or Peptide-MHC-Based CAR Therapies for Targeted Elimination of Antigen-Specific B or T Cells in Hypersensitivity Disorders Such as Allergies and Autoimmune Diseases.* Cells, 2025. **14**(10): p. 753.
33. Fife, B.T. and J.A. Bluestone, *Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.* Immunological reviews, 2008. **224**(1): p. 166-182.
34. Lotze, M.T., S.H. Olejniczak, and D. Skokos, *CD28 co-stimulation: novel insights and applications in cancer immunotherapy.* Nature Reviews Immunology, 2024. **24**(12): p. 878-895.
35. Almawash, S., *Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.* Cancers, 2025. **17**(5): p. 880.
36. Ewart, D., E.J. Peterson, and C.J. Steer. *A new era of genetic engineering for autoimmune and inflammatory diseases*. in *Seminars in Arthritis and Rheumatism*. 2019. Elsevier.
37. Wardell, C.M., D.A. Boardman, and M.K. Levings, *Harnessing the biology of regulatory T cells to treat disease.* Nature Reviews Drug Discovery, 2025. **24**(2): p. 93-111.
38. Correale, J. and E. Carnero Contentti, *Induction of immune tolerance in NMOSD and MOGAD.* Therapeutic Advances in Neurological Disorders, 2025. **18**: p. 17562864251357393.
39. Addissouky, T.A., *Beyond insulin: advancing frontiers in cell-based and genetic therapies for type 1 diabetes management.* The Egyptian Journal of Internal Medicine, 2025. **37**(1): p. 84.
40. Falcone, M. and G. Fousteri, *Role of the PD-1/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes.* Frontiers in endocrinology, 2020. **11**: p. 569.
41. Ling, X., et al., *IFN-γ-primed hUCMSCs significantly reduced inflammation via the Foxp3/ROR-γt/STAT3 signaling pathway in an animal model of multiple sclerosis.* Frontiers in immunology, 2022. **13**: p. 835345.
42. Tsai, Y.-G., et al., *Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.* Frontiers in immunology, 2023. **14**: p. 1230264.
43. Wang, S., et al., *Advances in experimental models of rheumatoid arthritis.* European

journal of immunology, 2023. **53**(1): p. 2249962.
44. Al Nabhani, Z., et al., *Nod2 protects the gut from experimental colitis spreading to small intestine.* Journal of Crohn's and Colitis, 2020. **14**(5): p. 669-679.
45. van Weijsten, M., *Antigen-specific targeting of autoreactive B-cells in Rheumatoid Arthritis*. 2024: Sl: sn.
46. Amini, L., et al., *Super-Treg: toward a new era of adoptive Treg therapy enabled by genetic modifications.* Frontiers in Immunology, 2021. **11**: p. 611638.
47. Hughes, K., *Development of Polymeric Nanoparticles and Complementary Diagnostics to Control Aberrant Immune Function*. 2020.
48. Afzal, M., et al., *Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine.* Trends in Immunotherapy, 2024. **8**(2).
49. Zahoor, M., et al., *Multiomics in autoimmune diseases*, in *Biological Insights of Multi-Omics Technologies in Human Diseases*. 2024, Elsevier. p. 167-191.
50. Lee, A., *Immune and muli-omic profiling for molecular classification and biomarker discovery in soft tissue sarcoma.* 2020.
51. Yaung, K.N., et al., *Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus.* The Lancet Rheumatology, 2023. **5**(3): p. e151-e165.
52. Nakano, M., Y. Iwasaki, and K. Fujio, *Transcriptomic studies of systemic lupus erythematosus.* Inflammation and Regeneration, 2021. **41**(1): p. 11.
53. Cossins, B., *Identifying the molecular signatures that shape the course of synovial pathology in inflammatory arthritis*. 2020, Cardiff University.
54. Zheng, G., Y. Lu, and H. Chen, *Deep Learning based Framework for Predicting Mild Cognitive Impairment Progression in Neurology Using Longitudinal MRI.* IEEE Access, 2025.
55. Long, G. and L. Li, *Leveraging Machine Learning Algorithms for Early Detection and Prognosis of Pediatric Autoimmune Diseases A Comprehensive Data-Driven Approach.* 2024.
56. Marcos-Zambrano, L.J., et al., *Applications of machine learning in human microbiome studies: a review on feature selection, biomarker identification, disease prediction and treatment.* Frontiers in microbiology, 2021. **12**: p. 634511.
57. Chen, E.C., *Systematic analysis of B-cell repertoires*. 2022, Vanderbilt University.
58. Hong, X., et al., *Single-cell RNA sequencing reveals the expansion of cytotoxic CD4+ T lymphocytes and a landscape of immune cells in primary Sjögren's syndrome.* Frontiers in immunology, 2021. **11**: p. 594658.
59. Vincenzo, M.D., *Review on multi-modal AI models to integrate imaging and omics data*. 2024.
60. Luo, R., et al., *High-throughput peptide arrays identify potential diagnostic autoantibody signatures in early-stage lung adenocarcinoma.* Cancer Epidemiology, Biomarkers & Prevention, 2023. **32**(5): p. 726-738.
61. Wu, L., A. John, and J.P. Simoes. *Predicting Psychological States using Machine Learning and Digital Biomarkers from wearable data*. in *14th Supporting Health by*

Technology Conference 2025. 2025.
62. Kumar, A. and D. Metta, *AI-driven precision oncology: predictive biomarker discovery and personalized treatment optimization using genomic data.* Int J Adv Res Publ Rev, 2024. **1**(3): p. 21-38.
63. Ma, W. and N. Baran, *Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy.* World Journal of Clinical Oncology, 2025. **16**(7): p. 104959.
64. Du, H., J. Wang, and Z. Wang, *Cardiovascular adverse effects of immunotherapy in cancer: insights and implications.* Frontiers in Oncology, 2025. **15**: p. 1601808.
65. Mathews, I.T., *Metabolite Mediators of Inflammation and Immunity*. 2020: University of California, San Diego.
66. Dougan, M., et al., *Understanding and treating the inflammatory adverse events of cancer immunotherapy.* Cell, 2021. **184**(6): p. 1575-1588.
67. Nandi, R., *Slowing Time: The Science, Promise, and Ethics of Human Longevity (2014–2025).* 2025.
68. Reddy, K.J., *Accessibility and Affordability of Technologies*, in *Innovations in Neurocognitive Rehabilitation: Harnessing Technology for Effective Therapy*. 2025, Springer. p. 285-304.
69. Scott, E.C., et al., *Trends in the approval of cancer therapies by the FDA in the twenty-first century.* Nature Reviews Drug Discovery, 2023. **22**(8): p. 625-640.
70. Al Achkar, M., et al., *Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study.* BMJ open, 2020. **10**(3): p. e032639.
71. Rai, V., et al., *Targeted Therapies in Cancer Treatment: Unveiling the Latest Breakthroughs and Promising Approaches.* Journal for Research in Applied Sciences and Biotechnology, 2024. **2**(6): p. 175-183.
72. Wang, V., et al., *Systematic review on CAR-T cell clinical trials up to 2022: academic center input.* Cancers, 2023. **15**(4): p. 1003.
73. Sharma, R., A. Gulati, and K. Chopra, *Era of surrogate endpoints and accelerated approvals: a comprehensive review on applicability, uncertainties, and challenges from regulatory, payer, and patient perspectives.* European Journal of Clinical Pharmacology, 2025: p. 1-19.
74. Lythgoe, M.P., et al., *From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.* The Lancet Oncology, 2023. **24**(4): p. e150-e160.
75. Ganeshpurkar, A., et al., *Regulatory Aspects of Cancer Immunotherapy*, in *Nanotechnology Based Strategies for Cancer Immunotherapy: Concepts, Design, and Clinical Applications*. 2025, Springer. p. 439-470.
76. Jung, S.M. and W.-U. Kim, *Targeted immunotherapy for autoimmune disease.* Immune network, 2022. **22**(1): p. e9.
77. Wang, J., et al., *Biomarker-driven oncology trial design and subgroup characterization: challenges and potential solutions.* JCO Precision Oncology, 2024. **8**: p. e2400116.

ISSN: 3093-4737

78. Burnett, T., et al., *Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.* BMC medicine, 2020. **18**(1): p. 352.
79. Angelis, A. and L.D. Phillips, *Advancing structured decision-making in drug regulation at the FDA and EMA.* British journal of clinical pharmacology, 2021. **87**(2): p. 395-405.
80. Mills, J.K., M.N. Chadwick, and L.H. Sigal, *Optimizing Recruitment and Biomarker Precision in Autoimmune and Rare Autoimmune Trials.*
81. Rao, D.A., *Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases.* Nature Reviews Rheumatology, 2025: p. 1-14.
82. Yang, B., et al., *The importance of developing reproducible primary endpoints for clinical trials in systemic lupus erythematosus.* Clinical Rheumatology, 2025. **44**(1): p. 183-192.
83. Wetwittayakhlang, P., et al., *Treatment targets in ulcerative colitis: is it time for all in, including histology?* Journal of Clinical Medicine, 2021. **10**(23): p. 5551.
84. Valsecchi, A.A. and M. Di Maio, *Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative Review.* Pharmaceutical Medicine, 2025: p. 1-12.
85. Rallis, K.S., et al., *Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.* World Journal of Clinical Oncology, 2022. **13**(6): p. 448.

How to cite this article: Ali et al. 92026). **Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms. Pan-African Journal of Health and Psychological Sciences. Vol 2, Issue 2, April-June 2026. https://doi.org/10.64261/txxhnb84.**

ISSN: 3093-4737

How to cite this article: Ali et al. 92026). **Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms. Pan-African Journal of Health and Psychological Sciences. Vol 2, Issue 2, April-June 2026. https://doi.org/10.64261/txxhnb84.**

ISSN: 3093-4737

How to cite this article: Ali et al. 92026). **Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms. Pan-African Journal of Health and Psychological Sciences. Vol 2, Issue 2, April-June 2026. https://doi.org/10.64261/txxhnb84.**

ISSN: 3093-4737

How to cite this article: Ali et al. 92026). **Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms. Pan-African Journal of Health and Psychological Sciences. Vol 2, Issue 2, April-June 2026. https://doi.org/10.64261/txxhnb84.**

ISSN: 3093-4737

How to cite this article: Ali et al. 92026). **Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms. Pan-African Journal of Health and Psychological Sciences. Vol 2, Issue 2, April-June 2026. https://doi.org/10.64261/txxhnb84.**